Burning Rock Biotech Limited (BNR) FinancialsBNRBurning Rock Biotech Limited

Burning Rock Biotech Limited (BNR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is In-hospital business, accounting for 48.9% of total sales, equivalent to CNY 52.76M. Other significant revenue streams include Central laboratory business and Pharma research and development services. Understanding this composition is critical for investors evaluating how BNR navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Burning Rock Biotech Limited maintains a gross margin of 72.58%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -13.36%, while the net margin is -13.66%. These profitability ratios, combined with a Return on Equity (ROE) of -12.82%, provide a clear picture of how effectively BNR converts its operational activities into shareholder value.

In the context of the broader market, BNR competes directly with industry leaders such as LFMD and PARK. With a market capitalization of $139.79M, it holds a leading position in the sector. When comparing efficiency, BNR's gross margin of 72.58% stands against LFMD's 88.82% and PARK's 13.73%. Such benchmarking helps identify whether Burning Rock Biotech Limited is trading at a premium or discount relative to its financial performance.

The company's gross margin is relatively strong at 72.58% for Q2 2026, but this is overshadowed by a net loss of RMB 18.41 million, and a declining revenue trend with a 9.4% year-over-year revenue decline in Q2 2026.